Repligen Corporation announced that the U.S. FDA has granted Fast Track designation for secretin for the treatment of pediatric autism. “We are very pleased that the FDA has designated this program for Fast Track status,” stated Walter C. Herlihy, President and CEO of Repligen Corporation. “We believe that this action affirms a heightened awareness to Read more about FDA Grants Fast Track Designation For Secretin[…]